Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
03/23/2023* -- Results Q4 2022 -- 0.06 --
08/10/2022 -- Results Q2 2022 0.15 0.08 79.00%
05/12/2022 -- Results Q1 2022 1.82 0.88 108.1%
03/23/2022 -- Results Q4 2021 4.89 1.66 194.8%
11/10/2021 -- Results Q3 2021 1.86 5.55 -66.46%
11/10/2021 16:30 EST Earnings Call Q3 2021 -- -- --
08/12/2021 -- Results Q2 2021 -0.75 -0.53 -41.10%
08/12/2021 08:00 EST Earnings Call Q2 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 03/23/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/10/2022
Beat/Miss Upgrade
Return Since -26.06%
Last FQE 09/30/2022
Next FQE 12/30/2022

Profile

Edit
ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.
URL https://www.iteostherapeutics.com
Investor Relations URL https://investors.iteostherapeutics.com/
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Mar. 23, 2023 (est.)
Last Earnings Release Aug. 10, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
--
--
--
--
--
--
37.67%
-56.98%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-13.26%
88.73%
8.89%
3.38%
42.33%
132.0%
84.07%
-36.63%
-65.94%
-36.32%
-81.84%
12.49%
51.87%
218.8%
27.43%
-39.11%
-59.15%
-67.80%
-28.59%
-49.84%
-47.69%
-93.17%
229.0%
-48.60%
-56.50%
-87.17%
63.37%
16.67%
-79.93%
-17.17%
8.91%
-45.97%
-84.33%
As of December 02, 2022.

Profile

Edit
ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.
URL https://www.iteostherapeutics.com
Investor Relations URL https://investors.iteostherapeutics.com/
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Mar. 23, 2023 (est.)
Last Earnings Release Aug. 10, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
CNCR 703450.0 USD 3.28%
XSVM 8.087M USD 1.10%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter ITOS Tweets